Introduction
120 people, and at least 60 deaths were reported over the next two years. [7] Recent analysis showed that the pandemic of 1918 and 1919 killed 50-100 million people.
[1] Today, with a world population which is more than three times than that of 1918, even a relatively mild pandemic could kill many millions. No one knows when the next outbreak will be, but it is due any time from now! Most important, it is difficult to know what structure the avian flu virus will take. The virus can improve its transmissibility among humans via two principal mechanisms. The first is a "reassortment" event in which genetic material is exchanged between human and avian virus during co-infection of a human and a pig. The second mechanism is a more gradual process of adaptive mutation, whereby the capability of the virus to bind to human cells increases during subsequent infections of humans. [8] Currently H5N1, is the virus strain of avian influenza in circulation in pandemic? The key step is to rapidly ramp up research related to the production of an effective vaccine against the virus. Vaccine development is rather slow. Even if the subtype of the pandemic strain is isolated, manufacturing a vaccine will take around 6-8 months. The 1918 Spanish influenza virus killed 25 million people worldwide, in 25 weeks [11] [12] [13] and hence a 6-8 months' period may prove too long a wait. Given the capacity of all the current international vaccine manufacturers, supplies during the 6-8 months' period would be limited to fewer than a billion monovalent doses. Hence, as many health officials agree, antivirals are likely to be the first line of defense.
Role of antivirals
The use of antivirals is recommended for the control of seasonal and pandemic influenza. (2) Neuraminidase (NA) inhibitors (zanamivir and oseltamivir). Adamantanes are effective only against influenza A and are associated with a rapid emergence of drug resistance and several toxic effects. Adamantine-resistant influenza A isolates are genetically stable; can be transmitted to susceptible contacts; are pathogenic and can be shed for prolonged periods in immunocompromised patients taking the drug. This limits the use of the adamantanes for the treatment of influenza. A meta analysis, [14] on the role of antivirals against influenza, has concluded that the use of amantidine and rimantidine should be discouraged. NA inhibitors (oseltamivir and zanamivir) should only be used in a serious epidemic or pandemic along Oseltamivir also inhibited the activity of viral NA in vitro; the IC 50 (mean concentration of oseltamivir required to inhibit NA activity by 50%) was 7+0.9 nanomolar for A/HK/156/97 and 15+0.7 nanomolar for A/HK/1074/99. Mice, infected with H5N1 or H9N2 viruses and treated with oseltamivir, were completely protected from death (the lowest effective dose was 1 mg/kg/day); had significantly reduced virus load in the lungs (P<0.01); and had undetectable level of virus in the brain (P<0.05 for mice treated with 0.1 mg/kg/day).
[18] Oseltamivir failed to prevent death or extend the length of survival in mice when treatment was delayed by 60 or more hours after inoculation. The combination of oseltamivir and rimantadine with other public health measures. As concerns over an significantly increased the number of survivors and the length outbreak mounted, governments around the world competed of survival in mice inoculated with high doses of virus as to stockpile Tamiflu (a Roche-licensed product of oseltamivir) compared with mice treated with the same doses of oseltamivir as the treatment option against influenza. Oseltamivir was and rimantadine, administered individually.
[18] discovered in the mid '90s, shortly after scientists in AustraliaOseltamivir inhibited virus replication in a series of tissue based Biota learned that the neuraminidase protein of the flu cultures, representing each of the 9 NA subtypes. The EC virus could be inhibited. [15] A second type of antiviral available oseltamivir required to inhibit virus replication ranged from 1 in the market is zanamavir (a GlaxoSmithKline product to 42 micromolar. The IC 50 required to reduce virus NA activity marketed as Relenza). Primarily, when it was first launched in each of the NA subtypes ranged from 1.9 to 69.2 nanomolar, during the 2000-01 flu season, the drug was a dud because it indicating that oseltamivir inhibited NA activity. Mice, infected was packaged as an inhaled powder. But faced with a virus as with H5N1 or H9N2 viruses and treated with oseltamivir, were deadly as H5N1, it became the mainstay of management in completely protected from death (at 0.1 and 1 mg/kg/day, avian flu influenza. As a class, NA inhibitors are effective respectively); had significantly reduced virus titers in the lungs against all neuraminidase subtypes and, therefore, against all (at 1 mg/kg/day); and had undetectable levels of virus strains of influenza, which is important considering the infectivity in the brain (at 0.1 and 1 mg/kg/day respectively).
[ increasing fears regarding the potential of a new influenza An avian influenza virus H7N7, which caused an outbreak pandemic, oseltamivir has received substantial media of avian influenza in poultry farm workers in the Netherlands attention. As the production capacity is limited, governments in 2003, was also susceptible to oseltamivir. The IC are stockpiling the drug.
oseltamivir for the H7N7 virus was 1.29 nanomolar Mechanism of action 1.19 to 1.40 nmol/L), which is within the range of IC Oseltamivir, a prodrug, is hydrolyzed to the active drug, zanamivir-sensitive H1N1 and H3N2 clinical isolates (0.2 to oseltamivir carboxylate. It inhibits the NA of influenza virus 6.8 nmol/L, dependent on isolate and assay). [7] with the possibility of alteration of virus particle aggregation Pharmacokinetics Oseltamivir is well absorbed orally and the concentration for NA inhibition is 0.003 mcg/mL or greater. [16] The mean maximum concentrations for oseltamivir phosphate and oseltamivir carboxylate, after a multiple 75 mg twice daily oral dose, were 65.2 and 348 ng/mL, respectively. The area under the curve (AUC) is 112 and 2719 ng.h/mL, respectively.
[20] Oral oseltamivir phosphate is readily absorbed and extensively converted to the active form, oseltamivir carboxylate, predominantly by hepatic esterases. The drug is 3-42% protein bound and the volume of distribution is 23-26 litres.
[20] The metabolite is eliminated entirely (greater than 99%) by renal excretion. The elimination half-life of oseltamivir phosphate (prodrug) is 1-3 h and its metabolite oseltamivir carboxylate (active drug) is 6-10 h. [16, 21] 
Indications
The treatment and prophylaxis of avian influenza, uncomplicated acute illness should be initiated in adults and children (above 1 year), who have been symptomatic for no more than 2 days. This applies for prophylaxis of influenza and hemopoietic stem cell transplant.
Safety profile
Oseltamivir has few adverse effects when administered for either treatment or prophylaxis. Adverse drug reactions are mentioned in Table 1 .
[23 -25] 
Place in clinical practice
Although oseltamivir has shown efficacy in the treatment of influenza, these findings must be placed in a clinical perspective. The agent has reduced the duration of symptoms
by approximately 1 day, a benefit which may not be worth the
effort to many patients with moderate illness, considering the nausea (10%) need to gain rapid access to a physician and a prescription, and to begin treatment within 24 h, for maximum benefit. The cost of treatment with these agents will be substantially higher as compared to the routine prevention with vaccine. A method Zanamivir of rapid viral diagnosis is not readily available as yet and hence headache (2%) many patients will be misdiagnosed and treated
inappropriately. With regard to prophylaxis, influenza vaccine
is preferred to the more costly therapy with oseltamivir.
diarrhoea (3% adults,
Comparative studies between drugs and vaccine are lacking.
2% children)
At present, the prevention of influenza with the current-season
vaccine is preferred and is less expensive than treatment or drug prophylaxis. Oseltamivir should be considered as an alternative for treatment of infection, primarily in high-risk groups (elderly patients, underlying cardiovascular/ respiratory influenza A (H5N1, H9N2, and H6N1); provided complete disease, renal dysfunction). The routine use of these agents in protection from death in mice infected with strains of H5N1, young patients is questionable. The selection of one agent over H9N2, and H6N1, when administered intranasally at doses of the other (oseltamivir vs zanamivir) will likely to be determined 50 mg/kg twice daily; and significantly reduced virus titer in by patient preference (inhalation Vs tablet) and comparative murine lungs. In vitro EC 50 of zanamivir, to effectively inhibit cost. A direct comparison of zanamivir with oseltamivir is virus replication, ranged from 8.5 to 14 micromolar. Zanamivir needed with respect to safety, efficacy and patient also inhibited the activity of viral NA in vitro. The IC zanamivir required to reduce NA activity ranged from 5 to 10 Clinical review of zanamivir nanomolar. Although virus titers in murine lungs were significantly reduced for each of the viruses tested, the only It is an inhalational antiviral agent against influenza. It was strain reduced to undetectable levels was H9N2.
[ Pharmacokinetics Zanamivir is marketed as a dry powder for inhalation as it is not orally bioavailable. Peak response against influenza A/B via inhalation is 72 h. [25] The time to peak concentration via inhalation is 0.75 to 2 h. Bioavailability via oral route is 2%, whereas by inhalation it is 4% to 25%. Zanamivir concentrations in the sputum were found to be least 52 fold above the IC 50 , 6, 12 and 24 h after a single 10 mg inhaled dose of zanamivir.
[29-31] The median zanamivir concentrations in the sputum were 1336, 304 and 47 ng/mL at 6, 12 and 24 h after a single 10 mg inhaled dose in healthy volunteers (n=6).
[30]
Systemic administration showed high blood concentrations, but essentially no antiviral activity and was related to poor respiratory secretion penetration (supports cell surface 
Mechanism of action
Zanamivir inhibits the NA of influenza virus, altering virus particle aggregation and release. It is a selective inhibitor of influenza A and B virus NA and inhibits viral cleavage of sialic acid from cell surface glycoconjugates, which inhibits the release of newly formed virus from the surface of infected cells. It also prevents viral spread across the mucous lining of the respiratory tract.
[27]
Activity against avian influenza
An avian influenza A virus (H7N7), which caused an outbreak in commercial poultry farms in the Netherlands in 2003, was found to be susceptible to zanamivir in vitro. The IC 50 was 3.94 nmol/L (95% CI 3.61 to 4.29 nmol/L), which is within the range of IC 50 for zanamivir-sensitive H1N1 and H3N2 clinical isolates (0.3 to 13.1 nmol/L). [7] Zanamivir inhibited in vitro replication and NA activity of 3 strains of avian activity). The volume of distribution was 16 L with minimal to no metabolism. Renal excretion was 4-17% (intranasal) and 87% (intravenous) and the elimination half life 1.6 -5.1 h.
[29-31]
Indications
The treatment of uncomplicated acute illness due to influenza virus in adults and children, older than 7 years, should only be initiated if symptomatic for no more than 2 days. It is FDA approved against influenza treatment and prophylaxis. It is also used against avian influenza, influenza virus A/B. [32] [33] [34] 
Safety profile
In general, zanamivir is well tolerated. Studies till date, is very rare. But emergence of resistance against the NA inhibitors is a matter of immediate concern that is disabling our influenza defenses. Two studies in Japan confirmed the oseltamivir resistant cases. [40, 41] However, the high rate of emerging resistance in these studies may have been due to the use of insufficient doses of the drug and the resultant failure to eradicate the virus. No virus resistant to zanamivir has yet been isolated from immunocompetent patients after treatment. Zanamivir resistance developed in an immunocompromised infant infected with influenza B virus.
[42] Structural analysis [43] predicted that the chemical structure of oseltamivir, differing from zanamivir, could facilitate the development, survival and propagation of drug-resistance virus. Molecular analysis [44] suggest that the adverse effects are primarily minor showed that the amino acid E276 must rotate and bond with upper respiratory and gastrointestinal symptoms. [35] [36] [37] [ Table 1 There are logistical problems with use -patients must gain can promote resistance. This may lessen the usefulness of first access to a physician rapidly at symptom onset, obtain line pharmacotherapy defense against influenza. immediate prescription, start medication on the first day of symptoms for maximum efficacy (without rapid viral Future therapy and research test, many will be misdiagnosed/treated inappropriately).
Combating a disease as nimble and adaptive as influenza

�
The maximum benefit of 1 day up to 2.5 days shortening of requires scientists and healthcare professionals to look for symptoms (i.e., started after 30 hours) may not outweigh new products and alternative methods of production apart from the inconveniences for many patients. the available antivirals. Current influenza virus vaccines consist
The cost factor is also a matter of concern. [45] Vaccine efficacy for the inactivated vaccine in 1998 trivalent influenza vaccine, antibody production was not preventing influenza is about 80%. However, it varies by year affected in a placebo-controlled trial of healthy volunteers depending on the match between the vaccine strains and the (n=138). The hemagglutination inhibition titers 4 weeks after epidemic strain. Protection begins about 2 weeks after influenza immunisation were statistically similar in the vaccination and generally persists for 6 months (only about 4 zanamivir and placebo groups. This data suggest that months in the elderly). Protection with live vaccine appears to transient concomitant zanamivir does not compromise the immune response to the influenza vaccine. Further studies in high-risk groups are required. [38] Cost effectiveness Zanamivir, if used within 36 h of symptom onset, can reduce the health-care cost in high risk groups (patients who are 65 years and older) with influenza. A cost-effective study used efficacy data from an Australian clinical trial to model an estimation of healthcare cost in the high risk population. Cost savings are based on avoidance of hospitalisations.
[39] Again future studies are needed to demonstrate the reduction of hospitalisation rate with zanamivir in the high-risk group.
Resistance against antivirals
A key advantage of the NA inhibitors and a major difference from the adamantanes is that the development of resistance [46] The available influenza vaccine formulation is depicted in Table 2 .
[47] The measures to prevent the spread of influenza A (H5N1) are provided in Table 3 .
[47]
Constant research is ongoing in the area of vacci nation.
[48-51] The issues to be considered in developing new and better vaccines are price per dose, speed and ease of production, choice of substrate to grow the virus in or to express viral antigens, cross-protection for variant strains, efficacy in general and in immunologically naive populations, safety and acceptance by the regulatory agencies and the public. Antivirals against avain invasion Table 2 Formulations of influenza vaccine Vaccine (source), dose, Formulation Age route and duration Inactivated (split virus) 0.5 ml (IM) x 1 dose annually for influenza prophy laxis in adults; in children 3-8 years, 0.5 ml IM x 1 or 2 doses; 2 nd dose is recommended for vaccine-naïve children and should be given at least 4 weeks after the first dose.
Fluarix (GlaxoSmithKline) 0.5 ml, injection >18 years Fluvirin (Chiron) 5 ml multidose >4 years 0.5 ml, injection >4 years Table 3 Prevention against avian influenza virus � Genetically engineered live and killed influenza virus vaccines: It permits the construction of high-yield 6:2 seed viruses by mixing the 6 plasmid DNAs from a good-growing laboratory strain with the HA and NA DNAs obtained by particles. Mass production of defective viruses can be cloning relevant genes from currently circulating viruses. achieved using complementing cell lines. Thus, within a 1-2 weeks period, the appropriate seed � Nano viricides: Also called chemical viruses, these are viruses could be generated for distribution to the synthetic chemicals which destroy specific targets while manufacturers.
Risk group Comments
Hospitalised patients
remaining invisible in their hydrophilic shells to the host's � Protein vaccines: Virus-Like Particle (VLP) vaccine immune system. comprises 3 co-expressed virus proteins -hemagluttin, � Universal vaccines: Influenza viruses continue to undergo neuraminidase and matrix M1 -which are injected into antigenic drift, which is mostly reflected in accumulating response.
The VLP lacks genetic material, so it cannot changes in the HA. This fact requires a change in the vaccine the body. replicate. But animal studies have shown that it triggers an immune response. � Cell-culture vaccines: Methods are under development for vaccine production using cell cultures instead of embryonic chicken eggs. Mammalian cell substrates can save 1-2 months of the egg production time. � Viral-vectored vaccine: Researchers are working on adenoviral-vector vaccine for H5N1 for the past 3 years. The production process involves attaching part of the bird flu gene, extracted through standard molecular techniques, to a relatively benign adenovirus. The vaccine is then injected into the host where in only it replicates as influenza proteins, without harming the host. � Replication-defective vaccines: Virus particles, which lack the gene for the nuclear export protein, will go through a single cycle of replication without forming infectious formulation or a re-examination of the seed strains, on an annual basis. A realistic approach is the design of more cross protective vaccines for use in interpandemic years and during pandemics. A study has been done to show the effects of vaccines based on the conserved extracellular portion of the M2 protein fused to the hepatitis B core protein.
[48] Such an immunogen may induce a cross-reactive response in the vaccinated host. Similarly, immunisation with the NA antigen is likely to induce responses that are more cross-reactive than those by the more variable HA. In both cases, protection will require immune responses which are more vigorous than what is seen after natural infection. Antibodies against NA and M2 proteins in infected humans are generally not protective. Thus, vaccines consisting of NA or M antigens would need to be made to induce a dramatically enhanced immune response. The influenza virus is most likely to evade any single drug. By targeting several points in the viral life cycle simultaneously with different drugs, we are more likely to discourage the emergence of resistance to all drugs at once. Apart from the above-mentioned advances, a combination of inhaled antiviral with oral drug may be of greater value as the virus spreads through droplet infection. Zanamivir is highly concentrated in the respiratory tract, 10-20% of the active compound reach the lungs and the rest is deposited in the oropharynx. [52] Oseltamivir carboxylate is widely distributed in the body; achieves high plasma levels and thus can act outside the respiratory tract. Further studies on combination therapy are needed to effectively combat the virus. Scientists, scholars, academicians, students, corporates, pharma industry and members of IAECs/ IACUCs are invited to attend this congress which promises to be a never-before learning experience and the first of its kind in Asia!
To register and know more about the conference, visit the congress website at www.icare-worldwide.org 
